Cerecor Inc. (NASDAQ: CERC) rose Friday, after the company disclosed that it has received US patent for CERC-301.
The Rockville, Md.-based Cerecor, a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,202, this week, which is directed to CERC 301, an oral, NR2B-specific, NMDA receptor antagonist.
CERC-301 is a selective NR2B-specific NMDA receptor antagonist with a unique mechanism of action tested in >375 subjects to date. CERC-301 is being developed for the treatment of Neurogenic Orthostatic Hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy and Pure Autonomic Failure.
CERC-301 has a rapid onset of action, which we believe will result in long-term effectiveness and fewer side effects than the leading nOH treatments currently available.
Perry Calias, who heads R&D at Cerecor, said, "This issued patent, in conjunction with the potential issuance of other multiple patent applications currently under review, provides Cerecor with intellectual property rights to 2035. The expansion of our intellectual property portfolio is an integral aspect of Cerecor’s clinical development and commercialization strategy."
The ’363 patent, and its foreign counterpart applications, are co-owned with Merck & Co. (NYSE: MRK). Cerecor has an exclusive, worldwide license from Merck to this patent family and two other patent families covering NR2B-specific, NMDA receptor antagonist for the development and commercialization of CERC 301 (formerly MK 0657) for all human indications.
Shares hiked 66 cents, or 14.6%, Friday to $5.16
Related Stories
